» Articles » PMID: 28401075

Repeated Remote Ischemic Conditioning Effect on Ankle-brachial Index in Diabetic Patients - A Randomized Control Trial

Overview
Journal Adv Biomed Res
Date 2017 Apr 13
PMID 28401075
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Remote ischemic preconditioning (RIPC) is a phenomenon where a short period of ischemia in one organ protects against further ischemia in the other organs. We hypothesized that RIPC occurring in diabetic patients with ankle brachial index (ABI) between 0.70 and 0.90 were included with peripheral arterial disease, would make the better coronary flow resulted in the increasing ABI.

Materials And Methods: This randomized clinical trial study was done in the Afshar Cardiovascular Hospital in Yazd between 2013 and 2014. Sixty participants were randomly divided into two groups (intervention and control groups). The intervention group was undergoing RIPC, and the control group was tested without RIPC. RIPC was stimulated by giving three cycles of 5 min of ischemia followed by 5 min of reperfusion of both upper arms using a blood pressure cuff inflated to 200 mm Hg ( = 30). This was compared with no RIPC group which consisted of placing a deflated blood pressure cuff on the upper limbs ( = 30).

Results: The mean of ABI level before intervention in the RIPC and control group group was 0.82 ± 0.055 and 0.83 ± 0.0603 ( = 0.347) respectively, with no significant difference. It was 0.86 ± 0.066 in the RIPC group compared the control 0.83 ± 0.0603 ( = 0.046). So levels of ABI were greater after intervention in the RIPC group. The mean of ABI level increase from 0.82 ± 0.05 to 0.86 ± 0.06 in RIPC group ( = 0.008). So the intervention group showed a significant increase in ABI.

Conclusions: RIPC through using a simple, noninvasive technique, composing three cycles of 5 min-ischemia of both upper arms, showing a significant increase in ABI level in diabetic patients.

Citing Articles

Chronic remote ischemic conditioning for cardiovascular protection.

Chong J, Bulluck H, Ho A, Boisvert W, Hausenloy D Cond Med. 2020; 2(4):164-169.

PMID: 32313876 PMC: 7169952.

References
1.
Przyklenk K, Li G, Whittaker P . No loss in the in vivo efficacy of ischemic preconditioning in middle-aged and old rabbits. J Am Coll Cardiol. 2001; 38(6):1741-7. DOI: 10.1016/s0735-1097(01)01603-5. View

2.
Rodrigo G, Samani N . Ischemic preconditioning of the whole heart confers protection on subsequently isolated ventricular myocytes. Am J Physiol Heart Circ Physiol. 2007; 294(1):H524-31. DOI: 10.1152/ajpheart.00980.2007. View

3.
Przyklenk K, Maynard M, Darling C, Whittaker P . Aging mouse hearts are refractory to infarct size reduction with post-conditioning. J Am Coll Cardiol. 2008; 51(14):1393-8. DOI: 10.1016/j.jacc.2007.11.070. View

4.
Przyklenk K, Heusch G . Late preconditioning against myocardial stunning. Does aspirin close the "second window" of endogenous cardioprotection?. J Am Coll Cardiol. 2003; 41(7):1195-7. DOI: 10.1016/s0735-1097(03)00087-1. View

5.
Przyklenk K . Efficacy of cardioprotective 'conditioning' strategies in aging and diabetic cohorts: the co-morbidity conundrum. Drugs Aging. 2011; 28(5):331-43. DOI: 10.2165/11587190-000000000-00000. View